82.47

1.14% -0.95

After Hours: 86.67 4.20 +5.09%

Intra Cellular Therapies Inc (ITCI)

Overview News Price History Option Chain Financials Discussions Forecast

Intra Cellular Therapies Inc stock is traded at $82.47, with a volume of 582.94K. It is down -1.14% in the last 24 hours and up +5.27% over the past month. Intra-Cellular Therapies Inc is a biopharmaceutical company that develops novel drugs for treating diseases of the central nervous system. The company is focused on the delivery and clinical development of small-molecule drugs that address needs in neuropsychiatric and neurological disorders. Intra-Cellular maintains proprietary chemistry platforms to develop drugs for neurodegenerative diseases. The company's business segment is discovering and developing drugs for the treatment of neurological and psychiatric disorders.

Previous Close:

$83.42

Open:

$83.56

24h Volume:

582.94K

Relative Volume:

1.08

Market Cap:

$8.82B

Revenue:

$612.78M

Net Income/Loss:

$-86.37M

P/E Ratio:

-51.22

EPS:

-1.61

Net Cash Flow:

$-62.91M

1W Performance:

-9.94%

1M Performance:

+5.27%

6M Performance:

+26.88%

1Y Performance:

+44.20%

1-Day Range:

$81.83

$83.61

1-Week Range:

$81.83

$91.52

52-Week Range:

$56.83

$93.45

Intra Cellular Therapies Inc Stock (ITCI) Company Profile

Name

Intra Cellular Therapies Inc

Sector

Healthcare (1204)

Industry

Drug Manufacturers - Specialty & Generic (87)

Phone

(646) 440-9333

Address

135 ROUTE 202/206, BEDMINSTER, NY

Employee

561

Twitter

Next Earnings Date

2024-10-30

Latest SEC Filings

ITCI's Discussions on Twitter

Compare ITCI with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
ITCI	82.47	8.82B	612.78M	-86.37M	-62.91M	-1.61
ZTS	176.42	79.51B	9.15B	2.43B	2.31B	4.92
TAK	13.53	42.89B	30.27B	1.93B	3.45B	0.444
HLN	9.43	42.57B	14.26B	1.55B	0	0.3327
TEVA	16.49	18.51B	16.77B	-959.00M	1.37B	-2.00
VTRS	13.00	15.37B	15.24B	-646.50M	1.88B	1.53

Intra Cellular Therapies Inc Stock (ITCI) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Sep-06-24	Upgrade	Piper Sandler	Neutral → Overweight
Jan-03-24	Initiated	Robert W. Baird	Outperform
Dec-11-23	Initiated	TD Cowen	Outperform
Apr-20-23	Initiated	Morgan Stanley	Overweight
Aug-22-22	Downgrade	Goldman	Buy → Neutral
Jul-07-22	Initiated	Mizuho	Buy
Jun-14-22	Initiated	UBS	Buy
Apr-22-22	Initiated	Piper Sandler	Neutral
Feb-16-22	Initiated	Goldman	Buy
Sep-23-21	Initiated	Needham	Buy
Dec-15-20	Initiated	BofA Securities	Buy
Dec-10-20	Initiated	Goldman	Buy
Feb-20-20	Initiated	Evercore ISI	Outperform
Jan-31-20	Downgrade	JP Morgan	Overweight → Neutral
Dec-24-19	Reiterated	Canaccord Genuity	Buy
Aug-12-19	Initiated	Jefferies	Buy
Feb-26-18	Initiated	JP Morgan	Overweight
Feb-08-18	Initiated	RBC Capital Mkts	Outperform
Dec-15-17	Initiated	Canaccord Genuity	Buy
Nov-08-17	Upgrade	SunTrust	Hold → Buy
Sep-07-17	Upgrade	Piper Jaffray	Neutral → Overweight
Aug-30-17	Upgrade	Ladenburg Thalmann	Neutral → Buy
Aug-24-17	Upgrade	JMP Securities	Mkt Perform → Mkt Outperform
Aug-23-17	Upgrade	Leerink Partners	Mkt Perform → Outperform
May-02-17	Downgrade	Ladenburg Thalmann	Buy → Neutral
May-02-17	Downgrade	Leerink Partners	Outperform → Mkt Perform
May-01-17	Downgrade	Piper Jaffray	Overweight → Neutral
Dec-16-16	Initiated	Cantor Fitzgerald	Overweight
Sep-29-16	Reiterated	RBC Capital Mkts	Outperform
Sep-29-16	Downgrade	SunTrust	Buy → Neutral

View All

Intra Cellular Therapies Inc Stock (ITCI) Latest News

Nov 16, 2024

Entropy Technologies LP Acquires Shares of 7,116 Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) - MarketBeat

Nov 16, 2024

Nov 15, 2024

Simplify Asset Management Inc. Increases Position in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) - MarketBeat

Nov 15, 2024

Nov 14, 2024

Intra-cellular therapies president sells $3.69 million in stock - Investing.com

Nov 14, 2024

Nov 13, 2024

Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) Position Increased by Aigen Investment Management LP - MarketBeat

Nov 13, 2024

FMR LLC Reduces Stake in Intra-Cellular Therapies Inc - GuruFocus.com

Nov 13, 2024

Nov 11, 2024

Intra-Cellular Therapies (NASDAQ:ITCI) Hits New 12-Month HighTime to Buy? - MarketBeat

Nov 11, 2024

Lisanti Capital Growth LLC Sells 24,760 Shares of Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) - MarketBeat

Nov 11, 2024

Intra-Cellular bolsters Caplyta data with another Phase III win - MSN

Nov 11, 2024

Principal Financial Group Inc. Acquires 18,865 Shares of Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) - MarketBeat

Nov 11, 2024

Nov 10, 2024

TimesSquare Capital Management LLC Grows Position in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) - MarketBeat

Nov 10, 2024

Nov 09, 2024

M&G Plc Invests $9.08 Million in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) - MarketBeat

Nov 09, 2024

Nov 08, 2024

Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) Shares Acquired by Wealth Enhancement Advisory Services LLC - MarketBeat

Nov 08, 2024

Nov 07, 2024

Intra-Cellular Therapies Stock Hits All-Time High of $90.37 - Investing.com India

Nov 07, 2024

Intra-Cellular Therapies Stock Hits All-Time High of $90.37 By Investing.com - Investing.com UK

Nov 07, 2024

Intra-Cellular Therapies Announces Presentations at the 2024 Psych Congress and NEI Congress - The Manila Times

Nov 07, 2024

Lifespeak Inc (LSPK-T) QuotePress Release - The Globe and Mail

Nov 07, 2024

Revenues Tell The Story For Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) As Its Stock Soars 26% - Simply Wall St

Nov 07, 2024

Nov 06, 2024